These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35514019)

  • 21. Gut microbiota modulation as a promising therapy with metformin in rats with non-alcoholic steatohepatitis: Role of LPS/TLR4 and autophagy pathways.
    Ahmed LA; Salem MB; Seif El-Din SH; El-Lakkany NM; Ahmed HO; Nasr SM; Hammam OA; Botros SS; Saleh S
    Eur J Pharmacol; 2020 Nov; 887():173461. PubMed ID: 32758573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Val-Val-Tyr-Pro protects against non-alcoholic steatohepatitis in mice by modulating the gut microbiota and gut-liver axis activation.
    Xie X; Zhang L; Yuan S; Li H; Zheng C; Xie S; Sun Y; Zhang C; Wang R; Jin Y
    J Cell Mol Med; 2021 Feb; 25(3):1439-1455. PubMed ID: 33400402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alanyl-Glutamine Protects Mice against Methionine- and Choline-Deficient-Diet-Induced Steatohepatitis and Fibrosis by Modulating Oxidative Stress and Inflammation.
    Hu J; Zheng Y; Ying H; Ma H; Li L; Zhao Y
    Nutrients; 2022 Sep; 14(18):. PubMed ID: 36145172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blocking integrin α
    Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
    J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
    Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis.
    Endo H; Niioka M; Kobayashi N; Tanaka M; Watanabe T
    PLoS One; 2013; 8(5):e63388. PubMed ID: 23696823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice.
    Rubio C; Puerto M; García-Rodríquez JJ; Lu VB; García-Martínez I; Alén R; Sanmartín-Salinas P; Toledo-Lobo MV; Saiz J; Ruperez J; Barbas C; Menchén L; Gribble FM; Reimann F; Guijarro LG; Carrascosa JM; Valverde ÁM
    Mol Metab; 2020 May; 35():100954. PubMed ID: 32244182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Schisantherin A alleviates non-alcoholic fatty liver disease by restoring intestinal barrier function.
    Yu S; Jiang J; Li Q; Liu X; Wang Z; Yang L; Ding L
    Front Cell Infect Microbiol; 2022; 12():855008. PubMed ID: 36132991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice.
    Arakawa K; Ishigami T; Nakai-Sugiyama M; Chen L; Doi H; Kino T; Minegishi S; Saigoh-Teranaka S; Sasaki-Nakashima R; Hibi K; Kimura K; Tamura K
    PLoS One; 2019; 14(6):e0218096. PubMed ID: 31206525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats.
    Nishi T; Yamamoto Y; Yamagishi N; Iguchi M; Tamai H; Ito T; Tsuruo Y; Ichinose M; Kitano M; Ueyama T
    J Pharm Pharmacol; 2018 Mar; 70(3):383-392. PubMed ID: 29355950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of nicotine on choline-deficient, L-amino acid-defined diet-induced non-alcoholic steatohepatitis in rats.
    Kanamori H; Nakade Y; Yamauchi T; Sakamoto K; Inoue T; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sumida Y; Nakao H; Fukuzawa Y; Yoneda M
    PLoS One; 2017; 12(6):e0180475. PubMed ID: 28662136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis.
    Schneider KM; Mohs A; Kilic K; Candels LS; Elfers C; Bennek E; Schneider LB; Heymann F; Gassler N; Penders J; Trautwein C
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity.
    Yang M; Kimchi ET; Staveley-O'Carroll KF; Li G
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scoparone alleviates inflammation, apoptosis and fibrosis of non-alcoholic steatohepatitis by suppressing the TLR4/NF-κB signaling pathway in mice.
    Liu B; Deng X; Jiang Q; Li G; Zhang J; Zhang N; Xin S; Xu K
    Int Immunopharmacol; 2019 Oct; 75():105797. PubMed ID: 31421545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
    de Faria Ghetti F; Oliveira DG; de Oliveira JM; de Castro Ferreira LEVV; Cesar DE; Moreira APB
    Eur J Nutr; 2018 Apr; 57(3):861-876. PubMed ID: 28875318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melatonin alleviates diet-induced steatohepatitis by targeting multiple cell types in the liver to suppress inflammation and fibrosis.
    Xu L; Li H; Zhang O; Zhang F; Song M; Ma M; Zhao Y; Ding R; Li D; Dong Z; Jin S; Han W; Ding C
    J Mol Endocrinol; 2023 Jan; 70(1):. PubMed ID: 36356262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soyasaponin A
    Xiong F; Zheng Z; Xiao L; Su C; Chen J; Gu X; Tang J; Zhao Y; Luo H; Zha L
    Mol Nutr Food Res; 2021 Jul; 65(14):e2100067. PubMed ID: 34047448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
    Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
    Wang Q; Zhou H; Bu Q; Wei S; Li L; Zhou J; Zhou S; Su W; Liu M; Liu Z; Wang M; Lu L
    J Hepatol; 2022 Aug; 77(2):312-325. PubMed ID: 35292349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.
    Ye JZ; Li YT; Wu WR; Shi D; Fang DQ; Yang LY; Bian XY; Wu JJ; Wang Q; Jiang XW; Peng CG; Ye WC; Xia PC; Li LJ
    World J Gastroenterol; 2018 Jun; 24(23):2468-2481. PubMed ID: 29930468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.